1 |
Fang H, Ding Y, Xia S, Chen Q, Niu B. Loureirin B promotes insulin secretion through GLP-1R and AKT/PDX1 pathways. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175377] [Reference Citation Analysis]
|
2 |
Zhang J, Mo L, Huang H, Xu J, Fan Y, Li W, Wang H, Zhou C, Fang H, He W, Chen Z, Liu Y. Loureirin B downregulates osteoclast differentiation of bone marrow macrophages by targeting the MAPK signaling pathway. Sci Rep 2022;12:14382. [PMID: 35999378 DOI: 10.1038/s41598-022-18287-5] [Reference Citation Analysis]
|
3 |
Cheng M, Yang Z, Li R, Wu G, Zhang C. Loureirin B alleviates cardiac fibrosis by suppressing Pin1/TGF-β1 signaling. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174791] [Reference Citation Analysis]
|
4 |
Ikeda Y, Nagase N, Tsuji A, Kitagishi Y, Matsuda S. Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer’s disease. World J Biol Chem 2021; 12(6): 104-113 [PMID: 34904048 DOI: 10.4331/wjbc.v12.i6.104] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
5 |
Ding Y, Xia S, Fang H, Niu B, Chen Q. Loureirin B attenuates insulin resistance in HepG2 cells by regulating gluconeogenesis signaling pathway. Eur J Pharmacol 2021;910:174481. [PMID: 34481876 DOI: 10.1016/j.ejphar.2021.174481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|